

# Addressing the Growing Threat of Securities Class Actions in the Life Sciences Sector

December 6, 2016 | Client Update

Life sciences companies are frequent targets of securities litigation. Often, when a company discloses bad news about a developing device or drug, the company's stock price drops and plaintiffs' lawyers pounce. They claim that the company's prior statements about the drug or device were too rosy. The attached memorandum addresses that all-too-typical fact pattern and describes the body of case law that has developed for assessing liability when a company has offered opinions about a new potential product.

If you have any questions regarding the matters covered in this publication, please reach out to any of the lawyers listed below or your usual Davis Polk contact.

**Bruce K. Dallas**

+1 650 752 2022  
bruce.dallas@davispolk.com

**Alan F. Denenberg**

+1 650 752 2004  
alan.denenberg@davispolk.com

**Michael S. Flynn**

+1 212 450 4766  
michael.flynn@davispolk.com

**Edmund Polubinski**

+1 212 450 4695  
edmund.polubinski@davispolk.com

**Lawrence Portnoy**

+1 212 450 4874  
lawrence.portnoy@davispolk.com

**Neal Potischman**

+1 650 752 2021  
neal.potischman@davispolk.com

**James P. Rouhandeh**

+1 212 450 4835  
rouhandeh@davispolk.com

**Richard D. Truesdell, Jr.**

+1 212 450 4674  
richard.truesdell@davispolk.com

*This communication, which we believe may be of interest to our clients and friends of the firm, is for general information only. It is not a full analysis of the matters presented and should not be relied upon as legal advice. This may be considered attorney advertising in some jurisdictions. Please refer to the firm's privacy notice for further details.*

## Related materials

[Read the full update](#)